Antiretrovirals, Part 1: Overview, History, and Focus on Protease Inhibitors

Psychosomatics

Volumn 45, Issue 3, 2004, Pages 262-270

  Wynn, Gary H ^b   Zapor, Michael J ^b   Smith, Benjamin H ^b   Wortmann, Glenn ^b   Oesterheld, Jessica R ^b   Armstrong, Scott C ^b   Cozza, Kelly L ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BUDESONIDE; FLUTICASONE PROPIONATE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RAPAMYCIN; RISPERIDONE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TADALAFIL; TRAZODONE; UNINDEXED DRUG; VARDENAFIL; ZOLPIDEM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APPETITE DISORDER; BLEEDING; CARDIOVASCULAR DISEASE; CHEILITIS; COMA; CUSHING SYNDROME; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG METABOLISM; DRY EYE; DRY SKIN; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LACTIC ACIDOSIS; LEUKOCYTOCLASTIC VASCULITIS; LIPODYSTROPHY; LIVER TOXICITY; LIVER TRANSPLANTATION; MANIA; MENTAL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PARONYCHIA; PROTEINASE INHIBITION; RADIATION ENTEROPATHY; RASH; REVIEW; RHABDOMYOLYSIS; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TASTE DISORDER; TOXIC HEPATITIS; VIRUS INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 2442548462     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.45.3.262     Document Type: Article

References (68)

1. Henry K: The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000; 15:306-311
2. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-459
3. Heath KV, Singer J, O'Shaughnessy MV: Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:211-217
4. Bartlett JA: Addressing the challenge of adherence. J Acquir Immune Defic Syndr 2002; 29:S2-S10
5. Grimes RM, Lal L, Lewis: Frequency of medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trials 2002; 3:161-167
6. Sternhell PS, Corr MJ: Psychiatric morbidity and adherence to antiretroviral medication in patients with HIV/AIDS. Aust N Z J Psychiatry 2002; 36:528-533
7. d'Arminio Monforte A, Lepri AC, Rezza G: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507
8. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP; APROCO Cohort Study Group: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001; 2:38-45
9. Goldsmith DR, Perry CM: Atazanavir. Drugs 2003; 63:1679-1693
10. Tayrouz Y, Ganssmann B, Ding R: Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001; 70:405-414
11. Hardy H, Esch LDF, Morse GD: Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001; 35:343-351
12. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636
13. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group: Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193
14. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42:81-92
15. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, Finazzi R, de Mey I, Florence E, Dreezen C; Eurosupport Study Group: Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001; 15:1019-1023
16. Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W: Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002; 30:187-190
17. Gilden D: Protease inhibitors, sexual dysfunction and Viagra. GMHC Treat Issues 1999; 13:12.
18. Bartlett JG: The Johns Hopkins Hospital 2003 Guide to Medical Care of Patients With HIV Infection, 10th ed. Philadelphia, Lippincott Williams and Wilkins, 2003, pp 101-111
19. Lana R, Nunez M, Mendoza JL, Soriano V: Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. Med Clin (Barc) 2001; 117:607-610
20. Vandercam B, Moreau M, Horsmans C, Gala JL: Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir. Infection 1998; 26:313
21. Sulkowski MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23:183-194
22. Kato Y, Fujii T, Mizoguchi N, Takata N, Ueda K, Feldman MD, Kayser SR: Potential interaction between ritonavir and carbamazepine. Pharmacotherapy 2000; 20:851-854
23. Baldwin ZK, Ceraldi CC: Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 2003; 37:676-678
24. Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW: Fatal ergotism induced by an HIV protease inhibitor. Headache 2002; 42:694-695
25. Hare CB, Vu MP, Grunfeld C: Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002; 35:E111-E112, Epub2002
26. Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42:1141-1160
27. Fichtenbaum CJ, Gerber JG, Rosenkranz SL: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577
28. Armstrong SC, Cozza KL, Oesterheld JR: Med-psych drug-drug interactions update: statins. Psychosomatics 2002; 43:77-81
29. Jain AK, Venkataramanan R, Fridell JA: Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl 2002; 8:838-840
30. Jain AK, Venkataramanan R, Shapiro R: The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8:841-845
31. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J: Indinavir concentrations and St. John's wort. Lancet 2000; 355:547-548
32. Cozza KL, Armstrong SC, Oesterheld JR: Drug Interaction Principles in Medical Practice. Washington, DC, American Psychiatric Publishing, 2003
33. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C; AIDS Clinical Trials Group 365 Study Team: Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003; 73:159-169
34. Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R: The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2000; 20:549-553
35. Armstrong SC, Cozza KL: Consultation-liaison psychiatry drug-drug interactions update. Psychosomatics 2001; 42:269-272
36. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68:231-237
37. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J: St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53:75-82
38. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601
39. Perloff MD, vonMoltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000; 14:1287-1289
40. Huang L, Wring SA, Woolley JL: Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29:754-760
41. Perloff MD, vonMoltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoproteins expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90:1829-1837
42. Vishnuvardhan D, vonMoltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 2003; 17:1092-1094
43. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P: The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003; 37:476-482
44. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, Eap CB: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001; 23:553-555
45. Phillips EJ, Rachlis AR, Ito S: Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? AIDS 2003; 17:1577-1578
46. Albrecht D, Vieler T, Horst HA: Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis. AIDS 2002; 16:2098-2099
47. Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S: Nelfinavir urinary stones. J Urol 2002; 167:1384-1385
48. Moyano Calvo JL, Huesa Martinez I, Cruz Navarro N, Leal Arenas J, Leon Duenas E, Morales Lopez A, Maestro Duran JL, Ramirez Mendoza A: Urinary lithiasis secondary to indinavir in an HIV-positive patient. Arch Esp Urol 2001; 54:1117-1120
49. Rachline A, Lariven S, Descamps V, Grossin M, Bouvet E: Leucocytoclastic vasculitis and indinavir. Br J Dermatol 2000; 143:1112-1113
50. Rayner CR, Esch LD, Wynn HE: Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann Pharmacother 2001; 35:1391-1395
51. Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D: Fatal lactic acidosis and mimicking Guillain-Barre syndrome in an adolescent with human immunodeficiency virus infection. Pediatr Infect Dis J 2003; 22:668-670
52. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM: Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83:1-9
53. Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, Gallo RC: Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 1984; 224:503-505
54. Tosti A, Piraccini BM, D'Antuono A, Marzaduri S, Bettoli V: Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140:1165-1168
55. Wilde JT: Protease inhibitor therapy and bleeding. Haemophilia 2000; 6:487-490
56. Wu DS, Stoller ML: Indinavir urolithiasis. Curr Opin Urol 2000; 10:557-561
57. von Moltke LL, Durol AL, Duan SX, Greenblatt DJ: Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56:259-261
58. Hesse LM, vonMoltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with buproprion. Drug Metab Dispos 2001; 29:100-102
59. Jover F, Cuadrado JM, Andreu L, Merino J: Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002; 25:251-253
60. Kelly DV, Beique LC, Bowmer MI: Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36:827-830
61. Greenblatt DJ, vonMoltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI: Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43:414-422
62. Rotzinger S, Fang J, Coutts RT: Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 1998; 44:1185-1191
63. Sagir A, Wettstein M, Oette M, Erhardt A, Haussinger D: Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as a co-medication. AIDS 2002; 16:1191-1192
64. Gupta SK, Dubé MP: Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 2002; 35:E69-E71, Epub2002
65. Clevenbergh P, Corcostegui M, Gerard D, Hieronimus S, Mondain V, Chichmanian RM, Sadoul JL, Dellamonica P: Iatrogenic Cushing's syndrome in an HIV-infected patient with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 2002; 44:194-195
66. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR: Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46:111-116
67. Llibre JM, Romeu J, Lopez E, Sirera G: Severe interaction between ritonavir and acenocoumarol. Ann Pharmacother 2002; 36:621-623
68. Schonder KS, Shullo MA, Okusanya O: Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37:1793-1796